
The REVERSE trial evaluated rivaroxaban versus warfarin for anticoagulation in 250 patients after bioprosthetic valve surgery. This multicenter, randomized trial assesses a six-month treatment period, with primary outcomes including all-cause death, major cardiovascular events, and major bleeding. Safety is measured by ISTH-defined bleeding events.
Like
Save
Share